Product How it works Pricing Blog FAQ About Contact
Anika Therapeutics

Anika Therapeutics (NASDAQ: ANIK) net income

Anika Therapeutics reported a net loss of $10.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $56.4m. Earnings per share were −$0.76.

Anika Therapeutics's best year of the last 10 was fiscal 2016. The biggest drop was in fiscal 2018, −41.2%. It reported a loss in 5 of those 10 years.

Net income, in millions of US dollars32.5201631.8201718.7201827.22019-24.020204.12021-14.92022-82.72023-56.42024-10.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$10.9m—−9.6%−$0.76
2024−$56.4m—−47.0%−$3.83
2023−$82.7m—−68.4%−$5.64
2022−$14.9m−459.4%−13.1%−$1.02
2021$4.1m—2.8%$0.29
2020−$24.0m−188.2%−18.4%−$1.69
2019$27.2m+45.2%23.7%$1.93
2018$18.7m−41.2%17.7%$1.30
2017$31.8m−2.2%28.1%$2.18
2016$32.5m—31.5%$2.22

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Anika Therapeutics net income compared with its sector

By net income for its latest fiscal year, Anika Therapeutics ranks 192nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Anika Therapeutics, −9.6%.

RankCompanyNet incomeNet margin
190thCentury Therapeutics−$9.6m−8.8%
191stFennec Pharmaceuticals−$9.7m−21.8%
192ndAnika Therapeutics−$10.9m−9.6%
193rdAtriCure−$11.4m−2.1%
194thAirSculpt Technologies−$11.7m−7.7%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Anika Therapeutics

How much did Anika Therapeutics earn in fiscal 2025?
Anika Therapeutics reported a net loss of $10.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $56.4m.
What are the earnings per share of Anika Therapeutics?
They were −$0.76 in fiscal 2025, compared with −$3.83 in fiscal 2024.
What was the most profitable year for Anika Therapeutics?
Of its last 10 fiscal years, fiscal 2016, with $32.5m.
Where does Anika Therapeutics rank in its sector by net income?
It ranks 192nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Anika Therapeutics come from?
From the annual report (Form 10-K) that Anika Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Anika Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Anika Therapeutics: the Anika Therapeutics page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.